EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX:AIS) announced the commercial launch of Elestrin by the Kenwood Therapeutics Division of Bradley Pharmaceuticals, Inc.(NYSE:BDY). Elestrin is an effective ultra low dose transdermal estrogen therapy for the treatment of hot flashes in menopausal women which is delivered in Antares’ proprietary Advanced Transdermal Delivery (ATD™) gel system. Elestrin was approved by the Food and Drug Administration (FDA) in December, 2006. Bradley has exclusive marketing rights for Elestrin in the U.S. while Antares maintains the sole rights in Europe and elsewhere. Bradley in-licensed the product from Antares’ licensee BioSante Pharmaceuticals (AMEX:BPA).
